

Robert Brown

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/1418284/robert-brown-publications-by-year.pdf>

Version: 2024-04-09

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

| | | | |
|-------------------|-------------------------|-----------------|---------------|
| 51 papers | 5,021 citations | 28 h-index | 63 g-index |
| 63 ext. papers | 6,028 ext. citations | 10.4 avg, IF | 5 L-index |

| # | Paper | IF | Citations |
|----|--|------|-----------|
| 51 | Quantitative imaging of RAD51 expression as a marker of platinum resistance in ovarian cancer. <i>EMBO Molecular Medicine</i> , 2021 , 13, e13366 | 12 | 7 |
| 50 | Chromatin accessibility changes at intergenic regions are associated with ovarian cancer drug resistance. <i>Clinical Epigenetics</i> , 2021 , 13, 122 | 7.7 | 3 |
| 49 | Homologous recombination deficiency (HRD) score in germline BRCA2- versus ATM-altered prostate cancer. <i>Modern Pathology</i> , 2021 , 34, 1185-1193 | 9.8 | 15 |
| 48 | Transcriptional analysis of multiple ovarian cancer cohorts reveals prognostic and immunomodulatory consequences of ERV expression 2021 , 9, | | 5 |
| 47 | HNF4A and GATA6 Loss Reveals Therapeutically Actionable Subtypes in Pancreatic Cancer. <i>Cell Reports</i> , 2020 , 31, 107625 | 10.6 | 34 |
| 46 | Development and Validation of the Gene Expression Predictor of High-grade Serous Ovarian Carcinoma Molecular SubTYPE (ProTYPE). <i>Clinical Cancer Research</i> , 2020 , 26, 5411-5423 | 12.9 | 21 |
| 45 | Glycosylated Nanoparticles Derived from RAFT Polymerization for Effective Drug Delivery to Macrophages.. <i>ACS Applied Bio Materials</i> , 2020 , 3, 5775-5786 | 4.1 | 1 |
| 44 | International Cancer Microbiome Consortium consensus statement on the role of the human microbiome in carcinogenesis. <i>Gut</i> , 2019 , 68, 1624-1632 | 19.2 | 101 |
| 43 | Genes Predisposed to DNA Hypermethylation during Acquired Resistance to Chemotherapy Are Identified in Ovarian Tumors by Bivalent Chromatin Domains at Initial Diagnosis. <i>Cancer Research</i> , 2018 , 78, 1383-1391 | 10.1 | 19 |
| 42 | Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial. <i>Nature Medicine</i> , 2018 , 24, 628-637 | 50.5 | 410 |
| 41 | Biomarker Assessment of HR Deficiency, Tumor Mutations, and Copy Number in Ovarian Cancer: Associations with Clinical Outcome Following Platinum Monotherapy. <i>Molecular Cancer Research</i> , 2018 , 16, 1103-1111 | 6.6 | 42 |
| 40 | Is there a Role for Epigenetic Enhancement of Immunomodulatory Approaches to Cancer Treatment?. <i>Current Cancer Drug Targets</i> , 2018 , 18, 5-15 | 2.8 | 3 |
| 39 | Challenges and methodology in the incorporation of biomarkers in cancer clinical trials. <i>Critical Reviews in Oncology/Hematology</i> , 2017 , 110, 49-61 | 7 | 6 |
| 38 | Methylation of MYLK3 gene promoter region: a biomarker to stratify surgical care in ovarian cancer in a multicentre study. <i>British Journal of Cancer</i> , 2017 , 116, 1287-1293 | 8.7 | 14 |
| 37 | Super-achromatic monolithic microprobe for ultrahigh-resolution endoscopic optical coherence tomography at 800 nm. <i>Nature Communications</i> , 2017 , 8, 1531 | 17.4 | 41 |
| 36 | Platinum-Based Chemotherapy Induces Methylation Changes in Blood DNA Associated with Overall Survival in Patients with Ovarian Cancer. <i>Clinical Cancer Research</i> , 2017 , 23, 2213-2222 | 12.9 | 49 |
| 35 | Engineering solutions for cancer. <i>Convergent Science Physical Oncology</i> , 2017 , 3, 010201 | | |

| | | | |
|----|---|------|-----|
| 34 | Epigenetic Regulation of the Homeobox Gene MSX1 Associates with Platinum-Resistant Disease in High-Grade Serous Epithelial Ovarian Cancer. <i>Clinical Cancer Research</i> , 2016 , 22, 3097-3104 | 12.9 | 32 |
| 33 | Epithelial ovarian carcinoma diagnosis by desorption electrospray ionization mass spectrometry imaging. <i>Scientific Reports</i> , 2016 , 6, 39219 | 4.9 | 52 |
| 32 | Epigenetic mechanisms and therapeutic targets of chemotherapy resistance in epithelial ovarian cancer. <i>Annals of Medicine</i> , 2015 , 47, 359-69 | 1.5 | 41 |
| 31 | Transcriptional implications of intragenic DNA methylation in the oestrogen receptor alpha gene in breast cancer cells and tissues. <i>BMC Cancer</i> , 2015 , 15, 337 | 4.8 | 14 |
| 30 | Temporal stability and determinants of white blood cell DNA methylation in the breakthrough generations study. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2015 , 24, 221-9 | 4 | 43 |
| 29 | Dual EZH2 and EHMT2 histone methyltransferase inhibition increases biological efficacy in breast cancer cells. <i>Clinical Epigenetics</i> , 2015 , 7, 84 | 7.7 | 34 |
| 28 | Whole-genome characterization of chemoresistant ovarian cancer. <i>Nature</i> , 2015 , 521, 489-94 | 50.4 | 890 |
| 27 | DNA methylation profiling to assess pathogenicity of BRCA1 unclassified variants in breast cancer. <i>Epigenetics</i> , 2015 , 10, 1121-32 | 5.7 | 11 |
| 26 | Homologous recombination (HR) deficiency, tumor BRCA1/2 mutations (tmBRCA) and association with response and outcome following platinum monotherapy in high grade serous ovarian cancer (HGSOC).. <i>Journal of Clinical Oncology</i> , 2015 , 33, 5576-5576 | 2.2 | 2 |
| 25 | Nrf2, the master redox switch: the Achilles heel of ovarian cancer?. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2014 , 1846, 494-509 | 11.2 | 28 |
| 24 | Poised epigenetic states and acquired drug resistance in cancer. <i>Nature Reviews Cancer</i> , 2014 , 14, 747-53 | 31.3 | 195 |
| 23 | Variation in NF- κ B signaling pathways and survival in invasive epithelial ovarian cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2014 , 23, 1421-7 | 4 | 11 |
| 22 | Epigenetic Therapies in Solid Tumours: From Preclinical Models to Clinical Trial Results 2014 , 299-317 | | 0 |
| 21 | Promoter CpG island methylation of genes in key cancer pathways associates with clinical outcome in high-grade serous ovarian cancer. <i>Clinical Cancer Research</i> , 2013 , 19, 5788-5797 | 12.9 | 34 |
| 20 | Aberrant DNA methylation at genes associated with a stem cell-like phenotype in cholangiocarcinoma tumors. <i>Cancer Prevention Research</i> , 2013 , 6, 1348-55 | 3.2 | 20 |
| 19 | Tackling cancer burden in the Middle East: Qatar as an example. <i>Lancet Oncology, The</i> , 2012 , 13, e501-8 | 21.7 | 37 |
| 18 | Systematic CpG islands methylation profiling of genes in the wnt pathway in epithelial ovarian cancer identifies biomarkers of progression-free survival. <i>Clinical Cancer Research</i> , 2011 , 17, 4052-62 | 12.9 | 75 |
| 17 | Ovarian cancer stem cell-like side populations are enriched following chemotherapy and overexpress EZH2. <i>Molecular Cancer Therapeutics</i> , 2011 , 10, 325-35 | 6.1 | 168 |

16 Epigenetic Therapies **2011**, 189-202

| | | | |
|----|--|-------|------|
| 15 | Prospects for epigenetic compounds in the treatment of autoimmune disease. <i>Advances in Experimental Medicine and Biology</i> , 2011 , 711, 150-61 | 3.6 | 2 |
| 14 | Therapeutic modulation of epigenetic drivers of drug resistance in ovarian cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2010 , 2, 319-29 | 5.4 | 28 |
| 13 | The promises and pitfalls of epigenetic therapies in solid tumours. <i>European Journal of Cancer</i> , 2009 , 45, 1129-1136 | 7.5 | 78 |
| 12 | Approaches to target the genome and its epigenome in cancer. <i>Future Medicinal Chemistry</i> , 2009 , 1, 1481-95 | 4.95 | 9 |
| 11 | Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome. <i>Clinical Cancer Research</i> , 2008 , 14, 5198-208 | 12.9 | 1044 |
| 10 | Phase I and pharmacodynamic trial of the DNA methyltransferase inhibitor decitabine and carboplatin in solid tumors. <i>Journal of Clinical Oncology</i> , 2007 , 25, 4603-9 | 2.2 | 201 |
| 9 | Pharmacogenetic assessment of toxicity and outcome after platinum plus taxane chemotherapy in ovarian cancer: the Scottish Randomised Trial in Ovarian Cancer. <i>Journal of Clinical Oncology</i> , 2007 , 25, 4528-35 | 2.2 | 194 |
| 8 | ABCB1 2677G>T/A genotype and paclitaxel pharmacogenetics in ovarian cancer. <i>Clinical Cancer Research</i> , 2006 , 12, 4127; author reply 4127-9 | 12.9 | 24 |
| 7 | DNA methyltransferase inhibitors and the development of epigenetic cancer therapies. <i>Journal of the National Cancer Institute</i> , 2005 , 97, 1498-506 | 9.7 | 385 |
| 6 | Demethylation of the MCJ gene in stage III/IV epithelial ovarian cancer and response to chemotherapy. <i>Gynecologic Oncology</i> , 2005 , 97, 898-903 | 4.9 | 62 |
| 5 | CpG island methylation of DNA damage response genes in advanced ovarian cancer. <i>Cancer Research</i> , 2005 , 65, 8961-7 | 10.1 | 213 |
| 4 | The acquisition of hMLH1 methylation in plasma DNA after chemotherapy predicts poor survival for ovarian cancer patients. <i>Clinical Cancer Research</i> , 2004 , 10, 4420-6 | 12.9 | 216 |
| 3 | Epigenetic silencing mediated by CpG island methylation: potential as a therapeutic target and as a biomarker. <i>Drug Resistance Updates</i> , 2004 , 7, 267-78 | 23.2 | 98 |
| 2 | Epigenetic biomarkers in ovarian cancer | 31-40 | |
| 1 | Tumor mutational landscape is a record of the pre-malignant state | | 8 |